Best Oncology Companies in Norway
The 40 best Oncology companies in Norway in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: BerGenBio.
- Oncology R&D: emerging therapies and new challenges
- Oncology Market Size to Surpass USD 903.81 Billion by 2034
- Oncology Market Size Worth USD 668.26 Billion by 2034
Our analysis of 50 Oncology companies
$16.3b in tracked funding; 86% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Oncology companies in Norway
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BerGenBio Developer of therapeutics for cancer and severe respiratory infections | $74M | 76 mo ago | 45 | 2007 | — | Apple iCloud MailMicrosoft 365Node.js+16 | 52 patents AXL tyrosine kinase inhibition therapeutics, including small‑molecule inhibitors and antibodies. | — |
| 2 | Nordic Nanovector Developer of antibody radionuclide conjugates for haematological cancers | $52M | 55 mo ago | 40 40 → 24 (-40%) | 2009 | — | — | 98 patents Radioimmunotherapy antibodies targeting CD37 for non‑Hodgkin lymphoma treatment | 1 job opening |
| 3 | Ultimovacs Developer of next-generation cell therapies for solid tumors | $32M | 58 mo ago | 25 | 2011 | — | — | 29 patents Therapeutic cancer vaccines combining telomerase antigens with immune‑checkpoint inhibition | — |
| 4 | Cytovation Developerof peptide therapeutics to treat cutaneous warts caused by HPV | $32M | 16 mo ago | 10 | 2001 | Lars Prestegarden CEO | WordPressMySQLPHP+21 | 31 patents Peptide-based therapeutic compositions and combination regimens for cancer treatment | — |
| 5 | Oncoinvent Developer of radioisotope-based anti-cancer therapeutics | $31M | 75 mo ago | 27 27 → 50 (+85%) | 2010 | — | WordPressMySQLPHP+17 | 43 patents Patents concentrated in health & consumer products | — |
| 6 | Algeta Developing alpha particle-emitting pharmaceutical with an anti-tumor effect for the treatment of cancer. | $29M | 251 mo ago | 175 | 1997 | — | — | 56 patents Targeted alpha‑emitting radiopharmaceuticals (Thorium‑227) for soft‑tissue and bone cancer therapy | — |
| 7 | Lytix Biopharma Developer of oncolytic peptide immunotherapy for solid tumors | $20M | 20 mo ago | 7 | 2003 | — | — | 160 patents Oncolytic peptide therapeutics using chitosan delivery for cancer immunotherapy | — |
| 8 | EXACT Therapeutics Provider of sonoporation platform for diagnosis of multiple diseases | $16M | 73 mo ago | 7 | 2012 | Masha Stromme CEO | Cart FunctionalitySquarespace CommerceSquarespace+11 | 48 patents Therapeutic ultrasound platforms for drug delivery, dose estimation, and bubble‑enhanced ablation. | — |
| 9 | Zelluna Immunotherapy Developer of TCR-based therapies for a wide range of cancer types | $8M | 48 mo ago | 18 18 → 23 (+28%) | 2016 | — | WordPress Block EditorWordPressMySQL+19 | 5 patents Engineered NK cell therapies and MAGE‑A4 specific TCR‑modified T cell immunotherapies | — |
| 10 | Targovax Vaccine and adenovirus-based immunotherapy to treat different cancer such as pancreatic, mesothelioma… | $6M | 159 mo ago | 23 | 2010 | — | — | 8 patents Peptide-based cancer immunotherapies targeting mutant RAS and combined chemotherapeutic regimens | — |
| 11 | APIM Therapeutics Developer of anti-cancer therapies potentiating chemotherapy induced responses in cancer cells | $4M | 63 mo ago | 1 | 2009 | — | — | 37 patents Peptide-based therapeutics targeting PCNA interaction motifs for sarcoma treatment | — |
| 12 | Clavis Pharma Developer of novel small molecule therapeutics for cancer | $3M | 175 mo ago | — | 2001 | Carlos Roig Founder | — | 83 patents Targeted nucleoside transporter antibodies and prodrug glucocorticoid/nucleoside chemotherapeutics | — |
| 13 | Augere Medical Provider of AI-based cancer detection device | $2M | 21 mo ago | 4 | 2018 | — | WordPressMySQLPHP+11 | 6 patents Real-time video object/pattern detection for medical imaging diagnostics | — |
| 14 | Nykode Therapeutics Developer of vaccines and immunotherapeutics for cancer and infectious diseases | $961K | 138 mo ago | 102 102 → 73 (-28%) | 2006 | Agnete Fredriksen Co-Founder & Chief Business Officer | WordPressApple iCloud MailMicrosoft 365+23 | 110 patents Protein-based immunogenic constructs and neoepitope cancer vaccines | — |
| 15 | Circio Developer of immunotherapies for cancer treatment | $956K | 20 mo ago | 17 | 2010 | Erik Digman Wiklund Chief Executive Officer | WordPressMySQLPHP+19 | — | 1 partnership |
| 16 | HBC Immunology Developer of peptide-based therapeutics for solid tumors | $900K | 36 mo ago | — | — | Bomi Framroze CEO | — | — | — |
| 17 | Hubro Therapeutics Developer of immunotherapies for cancer treatment | $164K | 85 mo ago | 5 | 2018 | Jon Eriksen CEO | — | 45 patents Design and synthesis of therapeutic peptides and diagnostic primer cocktails | — |
Top 12 Oncology companies in Norway
#1
Series A · Bergen, Vestland · founded 2001 · 10 employees$31.6Mraised▾
Developer of peptide therapeutics to treat cutaneous warts caused by HPV. The company's proprietary product, CyPep-1, is a peptide consisting of 27 amino acids with a mechanism that rapidly and selectively targets tumor cells due to altered electrochemical properties on their cell membranes not found on healthy cells.
- Apr 2025Series A$6M
- Jun 2023Series A$8M
- Jan 2022Series A$20M
- Jan 2018Series A$1.2M
#2
Public · Oslo, Oslo · founded 2003 · 7 employees$20.4Mraised▾
Lytix Biopharma develops oncolytic immunotherapies. Its lead candidate is LTX-315, an oncolytic peptide is being developed to treat solid cancer (phase I/II). It is also developing LTX-315 in combination with checkpoint inhibitors to treat cancer (preclinical/phase1) and a candidate under investigation for multidrug-resistant infections.
- Dec 2024Post IPO$9M
- Oct 2023Grant (prize money)$1.3M
- Aug 2017Series A$758.6K
- Dec 2015Series A$9.2M
#3
Seed · Oslo, Oslo · founded 2018 · 4 employees$2.1Mraised▾
Augere provides an AI-based cancer detection device. It analyses video in real-time. It can connect to any vendor's equipment. It gives the endoscopist a real-time probability of early-stage lesions.
- Nov 2024Seed$2.1M
#4
Public · Oslo, Oslo · founded 2010 · 17 employees$956.4Kraised▾
Developer of immunotherapies for cancer treatment. It offers circular RNA platform for developing medicines based on a modular genetic cassette design for expression of therapeutic proteins directly into cancer cells. It provides a lead candidate ONCOS-102 a monotherapy and in combinations with checkpoint inhibitors for melanoma, and TG01 is an immunotherapy targeting KRAS driver mutations for pancreatic cancer.
- Dec 2024Post IPO$956.4K
#5
Public · Oslo, Oslo · founded 2009 · 40 employees$51.7Mraised▾
Developer of antibody radionuclide conjugates for hematological cancers. The company's lead product includes Betalutin, an ARC that comprises a tumor-seeking anti-CD37 antibody conjugated to a low-intensity radionuclide (Lutetium 177). It is used to treat blood cancer non-Hodgkin Lymphoma.
- Jan 2022Post IPO—
- Feb 2021Post IPO—
- Sep 2020Post IPO$24.9M
- Dec 2019Post IPO$1.3M
#6
Public · Bergen, Vestland · founded 2007 · 45 employees$74.1Mraised▾
Developer of therapeutics for cancer and severe respiratory infections. It is a biopharmaceutical company focused on developing epithelial-mesenchymal transition inhibitors to treat aggressive cancers. It is using its own proprietary suite of complimentary technologies CellSelect used to identify and validate novel drug targets and biomarkers. Its lead product is BGB324, an Axl kinase inhibitor is in clinical trials for patients with Acute myeloid leukemia.
- May 2020Post IPO$49.8M
- Jan 2020Post IPO$24M
- Jun 2019Series C$8.7M
- Apr 2018Post IPO$24M
#7
Public · Oslo, Oslo · founded 2011 · 25 employees$32.3Mraised▾
Developer of next-generation cell therapies for solid tumors. The company has developed an immune-stimulatory vaccine UV1 (peptide epitopes from hTERT) vaccine targeting hTERT fragment expressing cancer cells to activate the immune response especially T-helper cells. It helps in treating prostate cancer and non-small cell lung carcinoma.
- Oct 2021Post IPO$32.3M
#8
Public · Oslo, Oslo · founded 2010 · 27 employees$30.7Mraised▾
Oncoinvent is developing radiotherapeutic, radio-immunotherapeutic and immunotherapeutic products for the treatment of various solid cancers. The company's radioisotopes are combined with carriers for optimal delivery of injected doses for the treatment of cancers. It's lead product cadherin which is an alpha-emitting radioactive microsphere designed for the treatment of metastatic cancers in peritoneal cavities. It has also developed proprietary antibodies (212Pb-labeled monoclonal antibodies) and holds a license for other antibodies.
- May 2020Series B$4M
- Feb 2017Series B$25M
- May 2016Series A$1.8M
#9
Series B · Oslo, Oslo · founded 2016 · 18 employees$8.4Mraised▾
Developer of TCR-based therapies for a wide range of cancer types. It offers T-cell receptor-guided natural killer (NK) cell therapies for solid tumors and multiple cancers.
- Aug 2022Series B—
- Jun 2020Series A$8.4M
- Jun 2020Grant (prize money)—
- 2016Seed—
#10
Late Stage · Oslo, Oslo · founded 2012 · 7 employees$16.5Mraised▾
EXACT Therapeutics provides a sonoporation platform for the diagnosis of multiple diseases. The company offers its flagship technology platform Acoustic Cluster Therapy (ACT) for targeting therapeutic enhancement. It is used for the ultrasound for the diagnosis of oncology (chemotherapy, immunotherapy), infectious diseases, and neurological conditions. The company is currently in Phase I of the clinical trial for a cancer diagnosis like for liver metastases, secondary to colorectal/pancreatic cancer among others.
- Jul 2020Post IPO$16.5M
#11
Seed · Alesund, More og Romsdal$900Kraised▾
Developer of peptide-based therapeutics for solid tumors
#12
Acquired · Oslo, Oslo · founded 1997 · 175 employees$29Mraised▾
In Dec 2013, Algeta was acquired by Bayer. Algeta (formerly Anticancer Therapeutic Inventions), an oncology company, focused on developing targeted therapies for patients with cancer-based on its alpha-pharmaceutical platform. Its lead product includes radium-223 dichloride, which completed Phase III clinical trial to treat castration-resistant prostate cancer with bone metastases. The company is also developing alpha-emitter thorium-227 that is in the preclinical phase linked to tumor-targeting molecules to form targeted thorium conjugates.
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Oncology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Oncology & Cancer Therapeutics is moving in Norway
A read on the academic research around Oncology & Cancer Therapeutics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 197 Norway-affiliated papers.
- Oslo University Hospital63
- University of Bergen39
- University of Oslo38
- Haukeland University Hospital18
- Drug Discovery Laboratory16
- Cancer research2→15
- Stromal cell1→5
- Tumor microenvironment3→46
- Immune system1→31
- Cancer research2→25
- Metastasis1→5
- Cell biology1→5
- Tumor microenvironment1→9
- Cancer research2→6
- Immunotherapy1→4
Where oncology is researched across Norway
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.